Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1824 • ACR Convergence 2025
Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
Roselyn Fierkens¹, Jun Inamo², Clara Lin³, Nathan Rogers⁴, Kari Hayes¹, Heather Leach³ and Kentaro Yomogida¹, ¹University of Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Children's Hospital Colorado, Aurora, ⁴Children’s Hospital Colorado, Aurora, CO
Background/Purpose: Natural Killer (NK) cells are the most abundant innate lymphoid cells, accounting for 10–40% of total lymphocytes in peripheral blood. They adapt to diverse…
Abstract Number: 1064 • ACR Convergence 2025
Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
Hayley M Lynch¹, Jordan E. Roberts¹ and James N. Jarvis², ¹Seattle Children's Hospital/UW, Seattle, WA, ²University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Several studies detail a higher prevalence and severity of juvenile idiopathic arthritis (JIA) in Indigenous North American (INA) children compared to the general population.…
Abstract Number: 0412 • ACR Convergence 2025
The Association of Obesity with Juvenile Spondyloarthritis
Katelyn Baggett¹, Timothy Brandon² and Pamela Weiss³, ¹Johns Hopkins University, Newtown Square, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Childhood obesity is a global public health concern that impacts the health and wellbeing of all children and particularly negatively affects children living with…
Abstract Number: 0392 • ACR Convergence 2025
Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)
Abigale Jagger¹, Mara Becker², Susan Thompson³, Mekibib Altaye⁴, John Bohnsack⁵, Hermine Brunner⁶, Margaret Chang⁷, Ashley Cooper⁸, Stefanie Davidson⁹, Alexandra Duell⁶, Bharti Gangwani⁷, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁷, Serena Pastore¹², Mariia Pavlenko¹³, Sampath Prahalad¹⁴, Megan Quinlan-Waters¹⁵, Laura Ramsey¹⁶, Grant Schulert⁶, Gabriele Simonini¹⁷, Erin Stahl⁸, Gabriele Stocco¹⁸, Marc Sudman¹⁹, Andrea Taddio¹⁸, Virginia Miraldi Utz⁶, Rae Yeung²⁰ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, ⁴Cincinnati Children's Hospital, Cincinnati, ⁵University of Utah, Salt Lake City, UT, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Boston Children's Hospital, Boston, MA, ⁸Children's Mercy Kansas City, Kansas City, MO, ⁹University of Pennsylvania/CHOP, Philadelphia, PA, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Institute of Child and Maternal Health - IRCCS "Burlo Garofolo", Trieste, Italy, ¹³Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁶Children's Mercy, Kansas City, MO, ¹⁷Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ¹⁸Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, ²⁰The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…
Abstract Number: 2150 • ACR Convergence 2025
Rheum to Grow:An Approach Towards Human Centered Design through a Qualitative Analysis on the Transition from Pediatric to Adult Rheumatology
Lillian Chang¹, Rhea Sharma², Elyse Guziewicz¹, Jordan Jackson³, Katrina Romagnoli¹, Gemme Campbell¹, Saritha Korukonda¹, Priyanka Pawar¹, Jonida Cote⁴, Thomas Davis¹ and Emily Brunner¹, ¹Geisinger, Danville, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Up to half of patients who transition to adult care are lost to follow up within 2 years of transfer from pediatric to adult…
Abstract Number: 1822 • ACR Convergence 2025
The Circulating Immune Profile of Systemic JIA Patients with HLA-DRB1*15 alleles, Eosinophilia, and Lung Disease
Jennifer Cheng¹, Alexandra Pommier², Ki Pui Lam³, Evan Hsu⁴, Courtney Leson⁵, Kyle McBrearty¹, Itohan Aigbekaen¹, Maryam Ashoor⁶, Ahmad Bakhsh¹, Carrie Bryant¹, Siobhan Case⁷, Mia Chandler¹, Margaret Chang¹, Ezra Cohen⁸, Fatma Dedeoglu¹, Olha Halyabar⁹, Jonathan Hausmann¹⁰, Melissa Hazen¹, Sonia Iosim¹, Liyoung Kim⁶, Jeffrey Lo¹, Mindy Lo¹, Emma Materne¹, Esra Meidan¹¹, Megan Perron¹², Helene Powers¹³, Mary Beth Son¹, Holly Wobma¹, Peter Nigrovic⁶, Alicia Casey¹, Joyce Chang¹, Pui Lee⁴ and Lauren Henderson¹⁴, ¹Boston Children's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ⁴Boston Children's Hospital, Newton, MA, ⁵Boston Children's Hospital, Boston, ⁶Boston Children's Hospital, Brookline, MA, ⁷UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁸Bmc, NEEDHAM, MA, ⁹Children's Hospital/Boston Medical Center, Newton, MA, ¹⁰Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ¹¹Boston Children's Hospital, Somerville, MA, ¹²Boston Children's Hospital, Natick, MA, ¹³Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹⁴Boston Children's Hospital, Watertown, MA
Background/Purpose: We aimed to explore the association between HLA-DRB1*15 alleles, eosinophilia, and lung disease (LD) in patients with systemic juvenile idiopathic arthritis (sJIA) through proteomic…
Abstract Number: 0824 • ACR Convergence 2025
Characterizing Immune Responses in Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
Lwiza AitDowd¹, Ekaterina Murzin², Alexandra Pommier³, Ki Pui Lam⁴, Claudia Harris⁵, Melanie Kohlheim⁶, Grant Schulert⁷, Marc Sudman⁸, Eveline Wu⁹, Laura Schanberg¹⁰, Peter Nigrovic¹¹, James Lederer¹² and Lauren Henderson¹³, ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Childrens Hospital, Boston, MA, ⁶CARRA, Granville, OH, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, ⁹UNC Chapel Hill, Chapel Hill, NC, ¹⁰Duke University Medical Center, DURHAM, NC, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Brigham and Women's Hospital, Millis, MA, ¹³Boston Children's Hospital, Watertown, MA
Background/Purpose: Our ability to tailor treatments to individual patients with JIA remains limited. To identify candidate biomarkers that may be associated with treatment response, we…
Abstract Number: 0411 • ACR Convergence 2025
Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Sheetal Vora², Catherine Bingham³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Katelyn Banschbach⁷, Jon Burnham⁸, Danielle Fair⁹, Mileka Gilbert¹⁰, Beth Gottlieb¹¹, Tzielan Lee¹², Melissa Mannion¹³, Edward Oberle¹⁴, Nancy Pan¹⁵, Natalie Rosenwasser¹⁶, Mary Toth¹⁷, Jennifer Weiss¹⁸ and Esi Morgan¹⁶, ¹Children's Mercy Kansas City, Overland Park, KS, ²Atrium Health Levine Children's Hospital, Charlotte, NC, ³Penn State Children's Hospital, Hershey, PA, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁶Seattle Children's Hospital, Burien, WA, ⁷cincinnati Children's hospital, Villa Hills, KY, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Cohen Children's Medical Center, Northwell Health, Lake Success, NY, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Nationwide Children's Hospital, Columbus, OH, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶Seattle Children's Hospital, seattle, WA, ¹⁷Nemours Foundation, Orlando, FL, ¹⁸Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network focused on improving healthcare delivery and outcomes in patients with…
Abstract Number: 0391 • ACR Convergence 2025
Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
Andrea Pilato¹, Giusyda Tarantino², Maria Isabella Petrone², Angela Aquilani², Emiliano Marasco², Rebecca Nicolai², Fabrizio De Benedetti³, Roberto Giacomelli⁴, Luca Navarini¹ and Silvia Magni-Manzoni², ¹University of Rome Campus Bio-Medico, Rome, Italy, ²Bambino Gesù IRCCS Children's Hospital, Rome, Italy, ³Bambino Gesu Children's Hospital, Rome, Rome, Italy, ⁴i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy
Background/Purpose: Monitoring disease activity is a crucial aspect of the treat to target paradigm in the management of rheumatic diseases. There are no standardized protocols…
Abstract Number: 2143 • ACR Convergence 2025
Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Jacqueline Madison¹, Andrew Grim² and Janna Shim³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medicine, Ann Arbor, MI, ³Midwestern University Chicago College of Osteopathic Medicine, Downers Grove
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s disease (AOSD) are rare, chronic, autoinflammatory diseases distinct from other forms of chronic inflammatory arthritis. Potential…
Abstract Number: 1821 • ACR Convergence 2025
Transcriptiomics of tear RNA from children with active and inactive chronic anterior uveitis
Donna Do¹, Brandon Michalidas², Mariia Pavlenko³, Alexandra Duell², Sheila Angeles-Han⁴ and Grant Schulert², ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Chronic anterior uveitis (CAU) is a potentially sight-limiting complication of pediatric rheumatic diseases, including juvenile idiopathic arthritis. However, the underlying inflammatory biology of CAU…
Abstract Number: 0819 • ACR Convergence 2025
Subcellular resolution spatial transcriptomics reveals immune-stromal crosstalk within the synovium of patients with juvenile idiopathic arthritis
Jun Inamo¹, Roselyn Fierkens², Michael Clay², Clara Lin³, Kari Hayes², Nathan Rogers⁴, Heather Leach² and Kentaro Yomogida², ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado, Aurora, CO, ³Children's Hospital Colorado, Aurora, CO, ⁴Children’s Hospital Colorado, Aurora, CO
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease, yet the spatial immune architecture of inflamed synovium remains poorly characterized. Prior…
Abstract Number: 0410 • ACR Convergence 2025
Improving Outcomes in Patients with Juvenile Idiopathic Arthritis through a Novel Chronic Condition Value-Based Care Program
Julia Harris¹, Emily Fox², Leslie Favier³, Michael Holland², Susan Parish⁴, Cara Hoffart⁴, Maria Ibarra², Jordan Jones⁴, Luke Harris⁴, Kristy Diederich⁴, Rachel Moran⁴, Amy Vickers⁴, Hannah Maasen⁴, Lydia Ottaviano⁴, Carlie Baldus⁴, Krysten Potter⁴, Melissa Erpelding⁴, Stephanie Quinn⁴ and Ashley Cooper⁴, ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Hospital, Kansas City, MO, ³Childrens mercy Hospital - Kansas City, Leawood, KS, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Outcomes for patients with juvenile idiopathic arthritis (JIA) are suboptimal with many patients having active disease, functional limitations, significant pain, and decreased health-related quality…
Abstract Number: 0389 • ACR Convergence 2025
An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis
Alessandra Alongi¹, Hermine Brunner², Angelo Ravelli³, Tadej Avcin⁴, Michael Beresford⁵, RUBEN BURGOS-VARGAS⁶, Ruben Cuttica⁷, Raju Khubchandani⁸, Ronald laxer⁹, Seza Özen¹⁰, Ross Petty¹¹, Carol Wallace¹², Nico Wulffraat¹³, Silvia Magni-Manzoni¹⁴, Marija Jelusic¹⁵, Alessandro Consolaro¹⁶, Jordi anton¹⁷, Gerd Horneff¹⁸, Mia Glerup¹⁹, Giovanni Filocamo²⁰, Gabriele Simonini²¹, ADELE CIVINO²², Agustin Remesal²³, Silvia Scala²⁴, Angela Pistorio²⁵, Daniel Lovell², Alberto Martini²⁶ and Nicolino Ruperto²⁷, ¹Università Milano Bicocca, Milan, Italy, Milano, Italy, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ⁴University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶Department of Rheumatology, Hospital General de Mexico, Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de México, Mexico, ⁷Hospital Pedro de Elizalde, Buenos Aires, Argentina, ⁸Jaslok Hospital and Research Center, Mumbai, India, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Hacettepe University Medical Faculty, Ankara, Turkey, ¹¹British Columbia Children’s Hospital, University of British Columbia, Vancouver, ON, Canada, ¹²Seattle Children's Hospital, University of Washington, Seattle, WA, ¹³Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁴Bambino Gesù IRCCS Children's Hospital, Rome, Italy, ¹⁵University Hospital Centre Zagreb, Zagreb, Croatia, ¹⁶IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹⁷Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, ¹⁸Asklepios Klinik, Hamburg, Germany, ¹⁹Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark, ²⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²¹Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ²²Department of Pediatric Immunology and Rheumatology, LECCE, Italy, ²³Hospital Universitario La Paz, Madrid, Spain, ²⁴Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁵Servizio di Epidemiologia e Biostatistica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁶Università degli Studi di Genova, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁷Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy
Background/Purpose: To improve the current classification criteria for juvenile idiopathic arthritis (JIA), a multi-step initiative coordinated by PRINTO was launched in 2015, starting with a…
Abstract Number: L09 • ACR Convergence 2024
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine Brunner¹, Caifeng Li², Kogie Chinniah³, Yosef Uziel⁴, Olga Synoverska⁵, Sujata Sawhney⁶, Inmaculada Calvo Penades⁷, Ingrid Clara Louw⁸, Meiping Lu⁹, Pooja Nikunj Patel¹⁰, Pamela F. Weiss¹¹, Cheng Chang¹², Ivana Vranic¹³, Shixue Liu¹⁴, Annette Diehl¹⁵, Jose L. Rivas¹⁶, Carol A. Connell¹⁷, Gary G. Koch¹⁸, Alberto Martini¹⁹, Daniel J. Lovell¹, Nicolino Ruperto²⁰ and the PRINTO and PRCSG investigators, ¹Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, ²Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, ³Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, ⁴Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, ⁵Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, ⁶Sir Ganga Ram Hospital, New Delhi, India, ⁷Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁸Panorama Medical Centre, Cape Town, South Africa, ⁹Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ¹⁰Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³Pfizer Ltd, Tadworth, United Kingdom, ¹⁴Pfizer Inc, Shanghai, China, ¹⁵Pfizer Inc, Collegeville, PA, ¹⁶Pfizer SLU, Madrid, Spain, ¹⁷Pfizer Inc, Groton, CT, ¹⁸University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹University of Genoa, Genoa, Italy, ²⁰Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…

« Previous Page
1
…
3
4
5
6
7
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].